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Introduction {#sec1}
============

Class switch recombination (CSR) is a B-lymphocyte-specific somatic recombination reaction that replaces the Cμ constant region of the immunoglobulin heavy chain (*Igh*) locus with one of the downstream constant genes ([@bib11], [@bib57]). As a consequence, B cells switch from expressing antibody molecules of the immunoglobulin M (IgM) class to IgG, IgE, or IgA, which harbor the same antigen specificity but a different effector function. This process is essential for the establishment of an effective immune response as evidenced by primary human immunodeficiency syndromes that are associated with defects in CSR ([@bib21]).

The *Igh* locus spans over 250 kb, and comprises a rearranged variable, diversity, and joining (VDJ) exon, encoding the variable portion of the antibody molecule, followed by exons encoding constant (C) regions (Cμ, Cγ3, Cγ1, Cγ2b, Cγ2a, Cε, and Cα in mice), each preceded by highly repetitive stretches of DNA, known as switch (S) regions. The *Igh* locus contains two important transcriptional enhancers, Eμ and 3′ regulatory region (3′RR) that are essential for B cell development and function. In addition to supporting *Igh* expression, Eμ is required for efficient V(D)J recombination and early B cell development ([@bib2], [@bib27], [@bib51], [@bib59]). The 3′RR is essential for late B cell differentiation, when it regulates antibody gene diversification by CSR and somatic hypermutation (SHM) in mature B cells ([@bib13], [@bib50], [@bib61], [@bib73], [@bib74], [@bib90]).

CSR is mediated by activation-induced deaminase (AID), which targets cytosine residues within the S regions of activated B cells ([@bib54], [@bib68]). The lesions induced by AID initiate a cascade of enzymatic reactions resulting in the formation of DNA double-strand breaks (DSBs) ([@bib8]). Paired breaks at donor and acceptor S regions are then repaired by components of the nonhomologous end-joining (NHEJ) pathway that includes Ku70/80, DNA ligase IV, 53BP1, and its downstream interactor Rif1, thus resulting in deletion of the intervening sequence and expression of the newly switched heavy chain ([@bib8], [@bib10], [@bib18], [@bib22]).

AID targeting is dependent on transcription across the S regions (germline transcription \[GLT\]), which exposes single-stranded DNA that is the substrate for this enzyme ([@bib12], [@bib19], [@bib67]). GLT is initiated at a promoter coupled with an I (intervening) exon located upstream of each S region and terminates downstream of the corresponding C~H~ gene ([@bib25], [@bib40], [@bib41], [@bib46], [@bib65], [@bib71], [@bib72]). Whereas transcription of the donor Sμ region is constitutive in naive B cells, GLT of acceptor regions is induced in a cytokine-dependent manner, which targets CSR to different isotypes ([@bib6], [@bib14], [@bib23], [@bib25], [@bib40], [@bib47], [@bib70], [@bib79], [@bib81], [@bib84], [@bib85]). The 3′RR acts as a major regulator of this process ([@bib7], [@bib62]). The 3′RR is located downstream of Cα and contains four lymphoid-specific transcriptional enhancers (DNase 1 hypersensitive sites hs3a, hs1,2, hs3b, and hs4) in mice ([@bib26], [@bib44], [@bib48], [@bib52], [@bib53], [@bib60]). hs1,2 is at the center of a ∼25-kb palindrome delimited by two inverted copies of the hs3 enhancers (hs3a and hs3b), with the distal hs4 module lying outside and downstream of the palindrome ([@bib7], [@bib62]). Both hs core enhancers and surrounding sequences have proven to be crucial to promote CSR by regulating GLT and accessibility of the S regions ([@bib13], [@bib24], [@bib39], [@bib50], [@bib61], [@bib75], [@bib90]). However, the mechanism by which the activity of the 3′RR is regulated has yet to be defined precisely.

Here, we identified zinc finger MYND-type containing 8 (ZMYND8) protein as a factor required for physiological levels of CSR. ZMYND8 is dispensable for repair of CSR breaks but acts upstream DSB formation by controlling 3′RR activity.

Results {#sec2}
=======

The Chromatin Reader ZMYND8 Is Required for CSR {#sec2.1}
-----------------------------------------------

To investigate the regulation of antibody diversification by CSR, we determined the protein interactome of the CSR and DSB repair factor Rif1 in switching B lymphocytes. To this end, we applied the proteomics-based technique isotopic differentiation of interactions as random or targeted (I-DIRT) ([@bib86]) to B lymphocytes stimulated to undergo CSR ([Figure S1](#mmc1){ref-type="supplementary-material"}). We employed primary cultures of splenocytes isolated from *Rif1*^*FH/FH*^ mice ([@bib16]), which express physiological levels of a knockin 1×Flag-2×hemagglutinin (HA)-tagged version of Rif1 that supports normal levels of CSR ([Figures S1](#mmc1){ref-type="supplementary-material"}A--S1C). As expected, the two top hits were the Rif1 bait and its phospho-dependent interactor 53BP1 ([Figures S1](#mmc1){ref-type="supplementary-material"}D and S1E). Several proteins exhibited I-DIRT ratios that were multiple SDs above the mean, suggesting that they are specifically associated with Rif1. Among these were a number of transcriptional regulators, including MGA, Zfp592, BACH2, TCEB1, and ZMYND8 ([Figures S1](#mmc1){ref-type="supplementary-material"}D and S1E).

To identify bona fide CSR factors, candidates with high I-DIRT ratio were assessed by somatic targeting using CRISPR-Cas9 in the B cell lymphoma line CH12 ([@bib55]; [Figures S1](#mmc1){ref-type="supplementary-material"}F and S1G). Upon cytokine stimulation, CH12 cells express AID and undergo class switching to IgA with high efficiency. Moreover, ablation of factors known to be essential for CSR, such as AID, 53BP1, and Rif1, reduces CSR in CH12 cells ([Figure S1](#mmc1){ref-type="supplementary-material"}G). Among the candidates tested, ZMYND8 showed the greatest impairment in CSR ([Figures 1](#fig1){ref-type="fig"}A, 1B, and [S1](#mmc1){ref-type="supplementary-material"}G). In agreement with the targeting results in bulk cultures, ZMYND8-deficient CH12 clones exhibited reduced levels of CSR compared to controls ([Figure 1](#fig1){ref-type="fig"}C). Furthermore, complementation of *Zmynd8*^*−/−*^ CH12 cell lines with full-length ZMYND8 fully rescued CSR, thus confirming that the defect is specifically caused by ZMYND8 deficiency ([Figure 1](#fig1){ref-type="fig"}D).Figure 1ZMYND8 Ablation in CH12 Impairs CSR(A) Scheme of *Zmynd8* genomic locus and location of guide RNAs (gRNAs) used in this study.(B) (Left top) Representative flow cytometry plots measuring CSR to IgA in activated Cas9/g*Zmynd8*-nucleofected CH12 cells. (Left bottom) Western blot analysis of whole-cell extracts from nucleofected CH12 cultures is shown. (Right) Summary dot plot indicating CSR as a percentage of the control (Ctrl) value within the same experiment is shown. The graph summarizes three independent experiments. *Aicda*, AID-encoding gene.(C) Graph depicting CSR to IgA in activated CH12 clonal derivatives. Each cell line was normalized to the mean value of the control clones, which was set to 100%. Graph is representative of at least two independent experiments.(D) (Left) Summary dot plot for four independent experiments measuring CSR to IgA 48 hr after activation of two *Zmynd8*^*−/−*^ CH12 cell lines (*KO*~*1*~ and *KO*~*2*~) reconstituted with either empty vector (EV) or full-length ZMYND8 (top legend). CSR is expressed as a percentage of the uninfected WT within the same experiment. (Right) Representative WB analysis of the CH12 cell lines is shown.Significance in (B) and (C) was calculated with the Mann-Whitney U test. Error bars in (D) represent SD. ^∗^p ≤ 0.05. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

To validate the I-DIRT result and confirm that ZMYND8 is a Rif1 interactor, we performed reciprocal co-immunoprecipitation experiments in primary B cells. We found that ZMYND8 was efficiently co-immunoprecipitated with Rif1 and vice versa ([Figures S1](#mmc1){ref-type="supplementary-material"}H and S1I). Ionizing irradiation (IR)-induced DNA damage resulted in the association between Rif1 and 53BP1 in a manner dependent on the DSB repair kinase ataxia-telangiectasia mutated (ATM) ([Figure S1](#mmc1){ref-type="supplementary-material"}H; [@bib18]). In contrast, ZMYND8 co-immunoprecipitated with Rif1 irrespective of DNA damage or ATM activity ([Figures S1](#mmc1){ref-type="supplementary-material"}H and S1I). We concluded that ZMYND8 interacts with Rif1 in a DNA-damage-independent manner.

To confirm the findings obtained in CH12 cells, we specifically deleted ZMYND8 in B cells by combining a *Zmynd8*^*F*^ conditional allele with *Cd19-Cre*, which drives Cre expression at early stages of B cell differentiation ([@bib69]; [Figure S2](#mmc1){ref-type="supplementary-material"}A). B cells from *Zmynd8*^*F/F*^*Cd19*^*Cre/+*^ mice developed normally ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C), thus indicating that ZMYND8 is dispensable for V(D)J recombination and B cell development. To assess whether ZMYND8 is required for CSR in primary B cells, we activated splenocytes with appropriate stimuli to induce switching to IgG1, IgG2b, and IgG3. ZMYND8 protein was readily detectable in resting B cells, and expression levels did not change following activation ([Figure S2](#mmc1){ref-type="supplementary-material"}D). Mature ZMYND8-deficient B cells showed a severe defect in CSR to all tested isotypes ([Figures 2](#fig2){ref-type="fig"}A--2C). To assess whether the defect we observed in primary B cell cultures reflected a reduced capability to mount a proper immune response *in vivo*, we immunized *Cd19*^*Cre/+*^ and *Zmynd8*^*F/F*^*Cd19*^*Cre/+*^ mice with the T-cell-dependent antigen 4-Hydroxy-3-nitrophenylacetyl hapten conjugated to Chicken Gamma Globulin (NP-CGG). The generation of NP-specific IgG1 antibodies was reduced nearly 5-fold in ZMYND8-deficient mice compared to control group ([Figure 2](#fig2){ref-type="fig"}D). We conclude that ZMYND8 is essential for physiologic levels of CSR in primary B lymphocytes.Figure 2ZMYND8 Is Required for CSR *In Vivo*(A--C) (Top) Representative flow cytometry plots measuring CSR to IgG1 (A), IgG2b (B), and IgG3 (C) in activated splenocytes. (Bottom) Summary dot plot for at least 5 mice per time point per genotype is shown.(D) NP-specific IgM and IgG1 antibody titers in serum collected before (day 0) and at day 7 and 20 after immunization with NP-CGG. NP-IgG1 antibodies were undetectable at day 0.Significance in (A)--(D) was calculated with the Mann-Whitney U test. Error bars in (A)--(D) represent SD. ^∗^p ≤ 0.05, ^∗∗^p ≤ 0.01, ^∗∗∗^p ≤ 0.001, ^∗∗∗∗^p ≤ 0.0001. See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

ZMYND8 Is Dispensable for DSB Repair {#sec2.2}
------------------------------------

CSR is dependent on the detection, signaling, and repair of AID-induced DSBs ([@bib8], [@bib57]). To determine whether loss of ZMYND8 alters any of these processes, we produced and analyzed ZMYND8-deficient mouse embryonic fibroblasts (MEFs) cell lines ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B). DSB signaling was measured by assaying for formation of IR-induced foci (IRIF) of γH2AX, 53BP1, and Rif1. In all cases, formation of DNA damage foci was normal in ZMYND8-deficient cell lines ([Figure S3](#mmc1){ref-type="supplementary-material"}C). Thus, ZMYND8 is not required for DSB detection and early IR-induced signaling in this model system.

In addition, *Zmynd8*^*−/−*^ MEFs and *Zmynd8*^*−/−*^ CH12 cell lines showed no measurable defect in survival after IR ([Figures S4](#mmc1){ref-type="supplementary-material"}A--S4C). Given reports that implicated ZMYND8 in homologous recombination (HR)-dependent repair of DSBs within transcriptionally active loci ([@bib28], [@bib29], [@bib37], [@bib83], [@bib94]), we assessed cell survival and genomic instability in response to treatment with PARP inhibitor (PARPi), which promotes DNA-replication-associated damage that is physiologically repaired by HR. ZMYND8-deficient MEFs displayed no increase in sensitivity to PARPi ([Figures S4](#mmc1){ref-type="supplementary-material"}D and S4E). Furthermore, DNA end protection from resection and repair of CRISPR-Cas9-induced DSBs were normal in *Zmynd8*^*−/−*^ CH12 cells ([Figures S4](#mmc1){ref-type="supplementary-material"}F and S4G). Altogether, these findings indicate that ZMYND8 is dispensable for DSB signaling and repair in MEFs and CH12 cells.

To determine whether ZMYND8 contributes to repair of AID-induced breaks, we analyzed residual Sμ-Sγ1 junctions cloned from *Zmynd8*^*F/F*^*Cd19*^*Cre/+*^ B cells stimulated with lipopolysaccharide (LPS) and interleukin-4 (IL-4). We found that the frequency and length of microhomology at the junctions were similar in *Cd19*^*Cre/+*^ and *Zmynd8*^*F/F*^*Cd19*^*Cre/+*^ mice, thus indicating that ZMYND8 deficiency does not bias the end-joining repair of AID-induced *Igh* breaks toward the use of microhomology ([Table S1](#mmc1){ref-type="supplementary-material"}). We concluded that ZMYND8 does not influence the choice between NHEJ and alternative end-joining (A-EJ) of S regions DSBs.

ZMYND8 Promotes Germline Transcription of Acceptor S Regions {#sec2.3}
------------------------------------------------------------

The level of CSR in activated B cells is directly dependent on the level of AID expression ([@bib20], [@bib87], [@bib88]). To determine whether decreased CSR in Zmynd*8*^*F/F*^*Cd19*^*Cre/+*^ splenocytes is due to altered AID expression, we measured AID mRNA by qPCR assays. AID expression in ZMYND8*-*deficient splenocytes was indistinguishable from controls ([Figures 3](#fig3){ref-type="fig"}A--3C). Moreover, a general survey of the transcriptome of *Zmynd8*^*−/−*^ and control CH12 cell lines by RNA sequencing (RNA-seq) ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B; [Tables S2](#mmc2){ref-type="supplementary-material"} and [S3](#mmc3){ref-type="supplementary-material"}) showed no downregulation of the expression of known CSR factors ([Figure S5](#mmc1){ref-type="supplementary-material"}C). We concluded that ZMYND8 deletion does not alter CSR by interfering with the expression of AID or other known essential regulators of CSR.Figure 3ZMYND8 Deficiency Causes Defective Germline Transcription of Acceptor S RegionsqPCR analysis for *Aicda* mRNA, Igμ, and Igγ1 (A), Igγ2b (B), and Igγ3 (C) GLT levels in B cells activated to undergo CSR to the corresponding isotypes. The schematic representations indicate the location of primers employed to analyze pre- and post-spliced germline transcripts. One *Cd19*^*Cre/+*^ mouse within each experiment was assigned an arbitrary value of 1 (error bars represent SD). Significance was calculated with the Mann-Whitney U test. ^∗∗^p ≤ 0.01, ^∗∗∗^p ≤ 0.001. See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

In addition to AID expression, CSR is dependent on normal cell cycle progression. To determine whether ZMYND8 deficiency is required for cell division in B cells, we analyzed the proliferation of activated *Zmynd8*^*F/F*^*Cd19*^*Cre/+*^ splenocytes by cell tracking dye dilution. The proliferation profile of ZMYND8-deficient B cells was indistinguishable from their wild-type (WT) counterpart at all time points after activation ([Figures S6](#mmc1){ref-type="supplementary-material"}A--S6C), whereas CSR levels were reduced irrespective of the cell cycle division stage ([Figure S6](#mmc1){ref-type="supplementary-material"}D). Furthermore, *Cd19*^*Cre/+*^ and *Zmynd8*^*F/F*^*Cd19*^*Cre/+*^ splenocytes exhibited similar growth curves following activation ([Figure S6](#mmc1){ref-type="supplementary-material"}E). These findings indicate that ZMYND8 deficiency does not alter cell proliferation in B cells.

AID targeting is dependent on noncoding transcription (GLT) across the S regions ([@bib11]). To examine the possibility that ZMYND8 promotes S region transcription, we measured GLT levels by qPCR at both donor (Sμ) and acceptor switch regions in ZMYND8*-*deficient splenocytes stimulated to undergo CSR to different isotypes. Sμ GLT was not affected by ZMYND8 depletion irrespective of the stimulation conditions ([Figures 3](#fig3){ref-type="fig"}A--3C), and we did not detect any significant decrease in the frequency of AID-induced mutations at 5′ Sμ in ZMYND8-deficient splenocytes ([Figures S6](#mmc1){ref-type="supplementary-material"}F and S6G). In contrast, both pre- and post-spliced acceptor GLTs were reduced in *Zmynd8*^*F/F*^*Cd19*^*Cre/+*^ cells ([Figures 3](#fig3){ref-type="fig"}A--3C), indicating the ZMYND8 deficiency specifically interferes with the induction of acceptor S region GLT. We next employed global nuclear run-on sequencing (GRO-seq) ([@bib15]) to visualize nascent RNA transcription at the *Igh* locus of B cells under stimulating conditions that induce GLTμ and ε and CSR to IgG1 and IgE ([Figures S5](#mmc1){ref-type="supplementary-material"}D and S5E). In agreement with the GLT qPCR results, ZMYND8-deficient cells exhibited lower levels of nascent RNA at Sγ1 and Sε, whereas transcription at donor Sμ was unaffected ([Figures S5](#mmc1){ref-type="supplementary-material"}D and S5E). We concluded that ZMYND8 is required to promote transcription of S acceptor regions and that the CSR defect of ZMYND8-deficient B cells is due to inefficient accessibility of these regions.

ZMYND8 Binds the *Igh* Enhancers and Represses Transcription at 3′RR {#sec2.4}
--------------------------------------------------------------------

ZMYND8 is a histone mark reader that associates with promoters and enhancers in several cell types and mediates either transcriptional activation or, more frequently, repression ([@bib1], [@bib3], [@bib4], [@bib43], [@bib49], [@bib63], [@bib78], [@bib80], [@bib83], [@bib97]). To examine the mechanism responsible for defective germline *Igh* transcription in *Zmynd8*^*−/−*^ B cells, we monitored ZMYND8 association with chromatin in CH12 by chromatin immunoprecipitation coupled with high-throughput sequencing (ChIP-seq). The vast majority of ZMYND8 peaks colocalized with promoters and distal intergenic regions ([Figure 4](#fig4){ref-type="fig"}A). To specifically assess whether ZMYND8 binds to super-enhancers in B cells, we defined the pool of B cell super-enhancers ([@bib64]) that overlapped with ZMYND8 peaks. Remarkably, ZMYND8 bound to nearly all of these regulatory elements ([Figure 4](#fig4){ref-type="fig"}B). Altogether, these findings indicate that ZMYND8 preferentially associates with promoters and super-enhancers in B cells.Figure 4ZMYND8 Binds Promoters and Super-Enhancers in B Cells(A) Genomic distribution of ZMYND8 ChIP-seq peaks in CH12 cells.(B) Venn diagram of the overlap between ZMYND8 peaks and B cells super-enhancers. SE, super-enhancer.(C) ZMYND8 occupancy at the *Igh* locus in WT and *Zmynd8*^*−/−*^ CH12 cell lines (*KO*~*1*~ and *KO*~*2*~). A schematic representation of the murine *Igh* locus showing location of enhancers (in gray) and S regions (in black) is represented below.Data in (A)--(C) are representative of two independent experiments.

The *Igh* locus contains two enhancer elements, Eμ and 3′RR, that are located at 5′ of Sμ and 3′ of Cα, respectively ([@bib7], [@bib58]). The 3′RR is a prototypical super-enhancer ([@bib62], [@bib92]), which is required for GLT induction and CSR in mature B lymphocytes and, to a lesser extent, in CH12 cells ([@bib33], [@bib36]). As expected from the genome-wide distribution ([Figures 4](#fig4){ref-type="fig"}A and 4B), ZMYND8 associates with the *Igh* locus in activated CH12 and B cells and it binds the 5′ Eμ and 3′RR enhancers ([Figures 4](#fig4){ref-type="fig"}C and [5](#fig5){ref-type="fig"}A).Figure 5ZMYND8 Represses 3′RR Enhancer Transcription(A) (Top) ZMYND8 and Pol II loading at the *Igh* locus in splenocytes stimulated for 72 hr with LPS and IL-4. (Bottom) Pol II ChIP-seq tracks overlay at regions encompassing Eμ and 3′RR enhancers.(B) Pol II loading quantification at *Igh* enhancers. Graph summarizes ChIP-seq data from three mice per genotype (error bars represent SD). Significance was calculated with Welch 2 sample unpaired t test.(C) qPCR analysis for hs1,2 and hs3b eRNA levels in B cells 48 hr after stimulation with LPS and IL-4 (left) or LPS only (right). Two sets of primers amplifying the 5′ (5′ hs3b) and 3′ (3′ hs3b) regions of hs3b were employed. The data summarize 4--6 mice per genotype (error bars represent SD). One *Cd19*^*Cre/+*^ mouse within each experiment was assigned an arbitrary value of 1.0. Significance was calculated with the Mann-Whitney U test.(D) (Left) Heatmap showing *Igh* 3′RR enhancers differential transcript expression as determined by RNA-seq in controls (WT bulk and clonal derivative WTc) and two independent *Zmynd8*^*−/−*^ CH12 clones (*KO*~*1*~ and *KO*~*2*~). Expression counts are row-normalized by *Z* score. Three independent RNA-seq replicates per sample are shown. (Right) Bar graphs depicting relative transcript levels at hs4, hs1,2, hs3b, and hs3a are shown. The adjusted p values were calculated with the Wald test and corrected for multiple testing with the Benjamini-Hochberg method.(E) (Left) Graph depicting ZMYND8-bound B cell super-enhancers that are differentially expressed in *Zmynd8*^*−/−*^ versus WT CH12 as measured by RNA-seq. DE SE, differentially expressed SE. (Right) Plot of fold change of Pol II loading on the differentially expressed super-enhancers defined in the left panel is shown.^∗∗^p ≤ 0.01. See also [Figure S7](#mmc1){ref-type="supplementary-material"} and [Table S4](#mmc4){ref-type="supplementary-material"}.

Loss of ZMYND8 results in enhancer overactivation as seen by increased enhancer RNA (eRNA) transcription ([@bib80]). To determine whether ZMYND8 occupancy at *Igh* enhancers alters their activity, we monitored RNA polymerase II (Pol II) occupancy at the *Igh* locus in ZMYND8-deficient cells by ChIP-seq. Pol II loading was significantly increased at the 3′RR core enhancers hs1,2 and hs3b in ZMYND8-deficient splenocytes and CH12 cells ([Figures 5](#fig5){ref-type="fig"}A, 5B, [S7](#mmc1){ref-type="supplementary-material"}A, and S7B). In contrast, no significant increase above controls was observed in *Rif1*^*−/−*^ cells ([Figures S7](#mmc1){ref-type="supplementary-material"}A and S7B). In agreement with increased Pol II loading, transcription of hs1,2 and hs3b eRNAs was increased in the absence of ZMYND8 both at the nascent (GRO-seq analysis; [Figure S5](#mmc1){ref-type="supplementary-material"}D) and steady-state levels ([Figures 5](#fig5){ref-type="fig"}C and 5D). These findings suggest that ZMYND8 modulates 3′RR function by suppressing its transcriptional activity.

To determine whether ZMYND8 controls the transcriptional status of B cell super-enhancers other than the *Igh*s, we analyzed the transcription profiles of ZMYND8-bound super-enhancers ([Figure 4](#fig4){ref-type="fig"}B) in the WT versus *Zmynd8-KO* cells. In total, 130 out of the 982 ZMYND8-occupied B cell super-enhancers were differentially expressed based on RNA-seq ([Figure 5](#fig5){ref-type="fig"}E; [Table S4](#mmc4){ref-type="supplementary-material"}; log2FoldChange \> 1; red and green dots). Of those, 90 displayed increased Pol II loading in the *Zmynd8-KO* cells when compared to WT ([Figure 5](#fig5){ref-type="fig"}E; log2FoldChange \> 0). Seven super-enhancers exhibited the most dramatic increase in Pol II loading in the absence of ZMYND8 ([Figure 5](#fig5){ref-type="fig"}E; log2FoldChange \> 1), with the 3′RR core enhancers hs1,2 and hs3b showing the highest enrichment. We concluded that ZMYND8 deficiency correlates with increased transcription of B cell super-enhancers.

ZMYND8 Is Required for Efficient SHM of the *Igh* Variable Region {#sec2.5}
-----------------------------------------------------------------

The 3′RR is also essential for somatic hypermutation of *Igh* variable region genes ([@bib73]). To determine whether ZMYND8 is required for SHM of the *Igh* variable regions, we sequenced the intronic region downstream the J~H~4 element of germinal center (GC) B cells from Peyer's patches of aged mice ([@bib34]). As expected, GC B cells from control mice displayed a high mutation frequency ([Figures 6](#fig6){ref-type="fig"}A, 6B, and 6E), which reflects the chronic nature of the B cell stimulation in Peyer's patches ([@bib30]). Nearly all sequences contained mutations (97%; 92/95), and a considerable portion of clones was heavily mutated ([Figures 6](#fig6){ref-type="fig"}A, 6B, and 6E). In contrast, GC B cells from *Zmynd8*^*F/F*^*CD19*^*Cre/+*^ mice accumulated mutations at a significantly lower rate ([Figures 6](#fig6){ref-type="fig"}A, 6C, and 6E), and the proportion of mutated sequences was decreased (77%; 94/122). Furthermore, when comparing the number of mutations per sequence, *Zmynd8*^*F/F*^*CD19*^*Cre/+*^ mice exhibited a skewed distribution with a considerable increase in the number of sequences bearing few mutations and the nearly complete absence of highly mutated clones ([Figures 6](#fig6){ref-type="fig"}A and 6C). We concluded that ZMYND8 ablation in mature B cells impairs SHM of the *Igh* locus.Figure 6ZMYND8 Is Required for Efficient SHM of the Heavy, but Not Light, *Ig* Chain(A and D) Cumulative pie charts showing percentage of sequences bearing indicated mutations in 3′ J~H~4 (A) and 3′ J~k~5 (D) regions cloned from sorted Peyer's patches B cells of aged unimmunized mice (4 mice per group). Total number of analyzed sequences is indicated below each pie chart. Mutations were quantified over 510 bp downstream J~H~4 gene segment and 536 bp downstream J~K~5 gene segment. GC, germinal center; NGC, non-germinal center.(B and C) Distribution of mutations per cloned sequences in individual *Cd19*^*Cre/+*^ (B) and *Zmynd8*^*F/F*^*Cd19*^*Cre/+*^ (C) mice.(E) Summary table listing number of analyzed sequences and total length, number of mutations, and mutation frequency at J~H~4 and J~K~5 introns in germinal center B cells from (A) and (D). Significance was calculated with the Mann-Whitney U test.

To assess whether ZMYND8 deficiency causes a general defect in somatic hypermutation, we analyzed SHM of the *Igk* locus, which is not controlled by the 3′RR. To do so, we monitored the mutation frequency immediately downstream J~K~5 gene segment ([@bib73]). We found a similar number of mutated sequences in ZMYND8-deficient (78%; 84/108) and control mice (83%; 88/106). Furthermore, both the distribution of mutations per sequence and mutation frequency were indistinguishable between the two groups ([Figures 6](#fig6){ref-type="fig"}D and 6E). Thus, ZMYND8 ablation specifically impairs the SHM process in the heavy-chain locus without affecting the k light-chain locus. Altogether, these findings indicate that, under physiologic conditions, ZMYND8 is an essential regulator of the 3′ *Igh* super-enhancer.

Discussion {#sec3}
==========

Despite initially identifying ZMYND8 as an interactor of the DNA repair factor Rif1, we were unable to document a significant effect of ZMYND8 in DSB repair in ZMYND8-deficient CH12 or MEF cells, irrespective of the source of DNA damage. This observation is consistent with the finding that the interaction between Rif1 and ZMYND8 in B cells undergoing CSR is not influenced by DNA damage or the ATM kinase. Pol II loading at the 3′RR was not altered in Rif1-deficient cells, thus indicating that, in contrast to ZMYND8, Rif1 does not act as a regulator of the 3′RR. Altogether, these results raise the possibility that the interaction between Rif1 and ZMYND8 might be accidental. However, we cannot exclude the intriguing possibility that Rif1 and ZMYND8 also contribute to CSR or other cellular functions by a common mechanism that is independent of their respective roles in DNA end protection and 3′RR regulation.

Mutation of the 3′RR in mice showed that it is necessary to support CSR and SHM ([@bib13], [@bib24], [@bib39], [@bib50], [@bib61], [@bib73], [@bib75], [@bib76], [@bib90]). More specifically, the 3′RR regulates the early steps of CSR, including donor and acceptor GLT transcription, Pol II pausing, AID targeting, and DSB formation; however, it is dispensable for resolution of CSR breaks and the DSB repair pathway choice between classical and alternative NHEJ. We have found that deletion of ZMYND8 increases 3′RR-transcriptional activity and phenocopies key aspects of the 3′RR deficiency. Consistent with this idea, ZMYND8 is necessary to support GLT of acceptor S regions and CSR. Furthermore, ZMYND8 deficiency impairs SHM specifically at the *Igh* locus. Given ZMYND8 association with 3′RR and its ability to repress enhancer transcription, these findings suggest that ZMYND8 is a key regulator of the 3′RR activity in mature B cells ([Figure 7](#fig7){ref-type="fig"}).Figure 7Model for ZMYND8 Function in *Igh* Gene DiversificationZMYND8 controls both CSR and *Igh* SHM via its ability to regulate the activity of the 3′ *Igh* super-enhancer. GTL for S-Cγ1 is representative of acceptor S region induction.

The spectrum of phenotypes exhibited by ZMYND8-deficient B cells and cells lacking the full 3′RR is not entirely overlapping. ZMYND8 acts on the accessibility of the acceptor S region rather than the donor Sμ region. In this regard, the phenotype of *Zmynd8*^*F/F*^*Cd19*^*Cre/+*^ cells is more reminiscent of B cells harboring deletions or replacements of some portions of the 3′RR (Δhs1,2 or Δ(hs3b-hs4); [@bib13], [@bib61]), which reduced GLT of several acceptor regions while leaving donor GLTμ unaffected. However, whereas these partial deletions within the 3′RR did not significantly affect γ1 GLT and switching to IgG1 ([@bib13], [@bib50], [@bib61]), ZMYND8 deficiency considerably reduced IgG1 CSR, albeit to a lesser extent than the full 3′RR deletion ([@bib75], [@bib90]). Given the intrinsic differences and degrees of phenotype penetrance exhibited by various deletions of internal portions of the 3′RR ([@bib5], [@bib13], [@bib24], [@bib39], [@bib50], [@bib61], [@bib76], [@bib89]), and the fact that ZMYND8 is a *trans*-acting factor that appears to differentially affect 3′RR modules, it is not at all surprising that ZMYND8 deficiency does not entirely phenocopy the full 3′RR deletion.

In plasma cells and resting B cells, the 3′RR contacts regions surrounding the 5′ Eμ enhancer (VDJ-Eμ), and upon activation, specific S regions are recruited into the VDJ-3′RR loop in a cytokine-dependent manner ([@bib35], [@bib93]). This topological organization is thought to facilitate both GLT expression and synapsis of recombining S regions. 4C analysis with a bait within the 3′RR did not show differences in the profile of long-range chromatin interactions within the *Igh* locus, suggesting that ZMYND8 binding to the *Igh* super-enhancers might not contribute to the establishment or maintenance of this architectural structure (data not shown).

Instead, the data support the possibility that ZMYND8 suppression of RNA Pol II loading on the 3′RR enhancer favors GLT transcription by removing local competition for *Igh* transcription factors. In support of this model, replacement of individual (hs1,2 or hs3a) or paired (hs3b and hs4) core enhancers with an actively transcribed neomycin gene cassette resulted in a more severe defect in acceptor GLT expression and CSR than deletion of the same modules ([@bib13], [@bib50], [@bib61]). Thus, deregulated transcription within the 3′RR interferes with its activity and disrupts the physiological regulation of GLT and CSR. Our data identify ZMYND8 as a key regulator of 3′RR transcriptional activity under physiologic circumstances.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Rat anti-CD40 Clone 1C10BioLegendCat\# 102810; RRID: [AB_629065](nif-antibody:AB_629065){#interref0010}Rat anti-CD180 (RP/14)BD BiosciencesCat\# 552128; RRID: [AB_394343](nif-antibody:AB_394343){#interref0015}Mouse anti-Flag M2Sigma-AldrichCat\# F3165; RRID: [AB_259529](nif-antibody:AB_259529){#interref0020}Mouse anti-Flag M2 (HRP conjugated)Sigma-AldrichCat\# A8592; RRID: [AB_439702](nif-antibody:AB_439702){#interref0025}Rabbit anti-Rif1[@bib18]N/ARabbit anti-ZMYND8Sigma-AldrichCat\# HPA020949; RRID: [AB_1857223](nif-antibody:AB_1857223){#interref0030}Mouse anti-γH2AX (Ser139) Clone JBW301Millipore/MerckCat\# 05-636; RRID: [AB_309864](nif-antibody:AB_309864){#interref0035}Mouse anti-β Actin Clone AC-15Sigma-AldrichCat\# A5441; RRID: [AB_476744](nif-antibody:AB_476744){#interref0040}Mouse anti-53BP1BethylCat\# A300-272A; RRID: [AB_185520](nif-antibody:AB_185520){#interref0045}Mouse anti-53BP1 Clone BP18Millipore/MerckCat\# 05-725; RRID: [AB_309939](nif-antibody:AB_309939){#interref0050}Mouse anti-RNA polymerase II CTD repeat YSPTSPS (phospho S5) Clone 4H8AbcamCat\# ab5408; RRID: [AB_304868](nif-antibody:AB_304868){#interref0055}Rat anti-CD21/CD35-FITC Clone 7G6BD BiosciencesCat\# 561769; RRID: [AB_10924591](nif-antibody:AB_10924591){#interref0060}Rat anti-IgD-FITC Clone 11-26c.2aBD BiosciencesCat\# 562022; RRID: [AB_10894208](nif-antibody:AB_10894208){#interref0065}Rat anti-IgM-PE Clone R6-60.2BD BiosciencesCat\# 553409; RRID: [AB_394845](nif-antibody:AB_394845){#interref0070}Rat anti-IgM-FITC Clone II/41BD BiosciencesCat\# 553437; RRID: [AB_394857](nif-antibody:AB_394857){#interref0075}Rat anti-CD43-PE Clone S7BD BiosciencesCat\# 561857; RRID: [AB_10926206](nif-antibody:AB_10926206){#interref0080}Rat anti-CD23-PE Clone B3B4BioLegendCat\# 101607; RRID: [AB_312832](nif-antibody:AB_312832){#interref0085}Rat anti-CD3-PE Clone 17A2BioLegendCat\# 100206; RRID: [AB_312663](nif-antibody:AB_312663){#interref0090}Rat anti-CD19-APC Clone 6D5BioLegendCat\# 115512; RRID: [AB_313647](nif-antibody:AB_313647){#interref0095}TruStain fcX Rat anti-CD16/32 Clone 93BioLegendCat\# 101320; RRID: [AB_1574975](nif-antibody:AB_1574975){#interref0100}Rat anti-B220/CD45R-FITC Clone RA3-6B2BioLegendCat\# 103205; RRID: [AB_312990](nif-antibody:AB_312990){#interref0105}Rat anti-CD38-Alexa700 Clone 90InvitrogenCat\# 56-0381-82; RRID: [AB_657740](nif-antibody:AB_657740){#interref0110}Hamster anti-CD95/Fas-PE Clone Jo2BD BiosciencesCat\# 561985; RRID: [AB_10895586](nif-antibody:AB_10895586){#interref0115}Rat anti-IgG2b-PE Clone RMG2b-1BioLegendCat\# 406707; RRID: [AB_2563380](nif-antibody:AB_2563380){#interref0120}Goat anti-IgA-PESouthern BiotechCat\# 1040-09Rat anti-IgG1-APC Clone X56BD BiosciencesCat\# 550874; RRID: [AB_398470](nif-antibody:AB_398470){#interref0125}Rat anti-IgG3-BIOT Clone R40-82BD BiosciencesCat\# 553401; RRID: [AB_394838](nif-antibody:AB_394838){#interref0130}Streptavidin-APCBD BiosciencesCat\# 554067; RRID: [AB_10050396](nif-antibody:AB_10050396){#interref0135}Streptavidin-AP ConjugateSigma-AldrichCat\# 11089161001Goat anti-Lamda-UNLBSouthern BiotechCat\# 1060-01Goat anti-Kappa-UNLBSouthern BiotechCat\# 1050-01; RRID: [AB_2737431](nif-antibody:AB_2737431){#interref0140}Mouse IgM-UNLB Clone 11E10Southern BiotechCat\# 0101-01; RRID: [AB_2629437](nif-antibody:AB_2629437){#interref0145}Mouse IgG1-UNLB Clone 15H6Southern BiotechCat\# 0102-01Goat anti-IgM, Human ads-BIOTSouthern BiotechCat\# 1020-08; RRID: [AB_2737441](nif-antibody:AB_2737441){#interref0150}Goat anti-IgG1, Human ads-BIOTSouthern BiotechCat\# 1070-08Rat anti-CD43 (Ly-48) MicrobeadsMiltenyi BiotecCat\# 130-049-801Goat anti-rabbit Alexa546InvitrogenCat\# A-11035; RRID: [AB_2534093](nif-antibody:AB_2534093){#interref0155}Goat anti-mouse Alexa488InvitrogenCat\# A-11029; RRID: [AB_2534088](nif-antibody:AB_2534088){#interref0160}Anti-BrdU beadsSanta Cruz BiotechCat\# sc-32323; RRID: [AB_626766](nif-antibody:AB_626766){#interref0165}**Chemicals, Peptides, and Recombinant Proteins**LPSSigma-AldrichCat\# L2630IL-4 (mouse recombinant)Sigma-AldrichCat\# I1020BAFF (human recombinant)PeproTechCat\# 310-13TGFβ-1 (mouse recombinant)R&D SystemsCat\# 7666-MB-005/CFPuromycin dihydrochlorideSigma-AldrichCat\# P8833SILAC-RPMIThermo ScientificCat\# 88421Dialyzed fetal bovine serumGIBCOCat\# 26400-044^13^C~6~ L-arginineCambridge Isotope LaboratoriesCat\# CLM-2265-H-PK-1^13^C~6~ L-lysineCambridge Isotope LaboratoriesCat\# CLM-2247-H-PK-1Non-labeled L-arginineSigma-AldrichCat\# A8094Non-labeled L-lysineSigma-AldrichCat\# L8662PolyvinylpyrrolidoneSigma-AldrichCat\# PVP40Complete EDTA-free protease inhibitor cocktailRocheCat\# 11873580001Phosphatase inhibitor cocktail tabletsRocheCat\# 04906837001BenzonaseSigma-AldrichCat\# E1014GlutaraldehydeSigma-AldrichCat\# 3408553XFlag peptideSigma-AldrichCat\# F4799NuPage LDS Sample bufferThermo Fisher ScientificCat\# NP0008ATMi KU55933Tocris BioscienceCat\# [3544](mi:3544){#intref0010}Carboxyfluorescein succinimidyl ester (CFSE)InvitrogenCat\# 65-0850-84CellTrace VioletThermo Fisher ScientificCat\# C34557AlumSigma-AldrichCat\# 31242 (Discontinued)NP-CGG~16~Biosearch TechnologiesCat\# N5055BParaformaldehydeSigma-AldrichCat\# P6148Crystal VioletSigmaCat\# C0775PARPi Olaparib/AZD2281, Ku-0059436SelleckchemCat\# S1060Pierce 16% Formaldehyde Methanol-freeThermo ScientificCat\# 28906TRIzolInvitrogenCat\# 15596018ColcemidSigma-AldrichCat\# 10295892001KaryoMAX Giemsa Stain SolutionGIBCOCat\# 10092013Gurr Buffer TabletsGIBCOCat\# 10582013Dynabeads Protein AInvitrogenCat\# 10001DDynabeads M-270 EpoxyInvitrogenCat\# 14301TRIzol LS ReagentInvitrogenCat\# 10296028**Critical Commercial Assays**Neon Transfection System, 100 μL KitInvitrogenCat\# MPK10025APC BrdU Flow KitBD BiosciencesCat\# 552598AllPrep DNA/RNA Mini Kit. DanQIAGENCat\# 80204Ribo-Zero Gold rRNA Removal KitIlluminaCat\# MRZG12324TruSeq Stranded Total RNA Library Prep KitIlluminaCat\# 20020597RNeasy Mini KitQIAGENCat\# 74104SuperScript VILO cDNA Synthesis KitInvitrogenCat\# 11754250RapidOut DNA Removal KitThermo ScientificCat\# K2981TOPO TA Cloning KitInvitrogenCat\# 450641Phusion High-Fidelity DNA PolymeraseThermo Scientific, NEBCat\# F530L, Cat\# M0530LLuna Universal qPCR MastermixNEBCat\# M3003NucleoSpin DNA Purification KitMacherey-NagelCat\# 740499TURBO DNaseInvitrogenCat\# AM2239RNA Fragmentation ReagentsInvitrogenCat\# AM8740BioSpin P-30 Gel ColumnsBio-RadCat\# 7326232T4 Polynucleotide KinaseNEBCat\# M0201LExonuclease INEBCat\# M0293LChIP DNA Clean and Concentrator KitZymo Research CorporationCat\# D5205RNase HThermo ScientificCat\# 18021071APE1NEBCat\# M0282L**Deposited Data**Raw and analyzed dataThis paperGEO: [GSE118794](ncbi-geo:GSE118794){#intref0015}Original scans and IF imagesThis paper; Mendeley Data<https://doi.org/10.17632/jktyjvy9hg.1>**Experimental Models: Cell Lines**Murine: CH12 (CH12F3) - WT, parental[@bib55]N/AMurine: CH12 - WTc, clonal derivativeThis paperN/AMurine: *AID*^*−/−*^ CH12This paper and KerafastCat\# ESP013Murine: *53bp1*^*−/−*^ CH12This paperN/AMurine: *Rif1*^*−/−*^ CH12This paperN/AMurine: *Zmynd8-KO*~*1*~ CH12This paperN/AMurine: *Zmynd8-KO*~*2*~ CH12This paperN/AMurine: *Zmynd8-KO*~*3*~ CH12This paperN/AMurine: iMEFs - WTc, clonal derivativeThis paperN/AMurine: iMEFs - Rc-1This paperN/AMurine: iMEFs - Rc-2This paperN/AMurine: *Zmynd8-KO*~*1*~ iMEFsThis paperN/AMurine: *Zmynd8-KO*~*2*~ iMEFsThis paperN/AMurine: *Zmynd8-KO*~*3*~ iMEFsThis paperN/A**Experimental Models: Organisms/Strains**Mouse: C57BL6: *WT*The Jackson LaboratoryJAX\# 664Mouse: *Rif1*^*FH/FH*^[@bib16]N/AMouse: *AID*^*−/−*^[@bib54]N/AMouse: *Zmynd8*^*tm1a*^European Mouse Mutant ArchiveEMMA\# 05720Mouse: *ROSA26*^*Flpo*^The Jackson LaboratoryJAX\# 007844Mouse: *Cd19*^*Cre/+*^[@bib69]N/AMouse: *Zmynd8*^*F/F*^This paperN/AMouse: *Zmynd8*^*F/F*^*Cd19*^*Cre/+*^This paperN/A**Oligonucleotides**ZMYND8 genotyping primersSee [Table S5](#mmc1){ref-type="supplementary-material"}N/AgRNAs for gene editingSee [Table S5](#mmc1){ref-type="supplementary-material"}N/APrimers for qPCRSee [Table S5](#mmc1){ref-type="supplementary-material"}N/AgRNAs for end resection assaySee [Table S5](#mmc1){ref-type="supplementary-material"}N/APrimers for end resection assaySee [Table S5](#mmc1){ref-type="supplementary-material"}N/APrimers for Sμ-Sγ1 junctionsSee [Table S5](#mmc1){ref-type="supplementary-material"}N/APrimers for SHMSee [Table S5](#mmc1){ref-type="supplementary-material"}N/A**Recombinant DNA**Plasmid: pMX-ZMYND8-3XFlagThis paperN/APlasmid: pX458 (pSpCas9(BB)-2A-GFP (PX458))AddgeneCat\# 48138Plasmid: pX458 expressing Cas9^D10A^This paperN/A**Software and Algorithms**MaxQuant (v.1.2.2.5)[@bib17]N/ABWA mem[@bib42]N/AHOMER ChIP-Seq program[@bib31]N/AR and ChIPseeker package[@bib96]N/Akallisto v.0.43.0[@bib9]N/AR package tximport[@bib82]N/ADESeq2[@bib45]N/ABowtie[@bib38]N/A

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Michela Di Virgilio (<michela.divirgilio@mdc-berlin.de>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

Source of cell lines and mouse models used in the study is reported in the [Key Resources Table](#sec4.1){ref-type="sec"}. All experiments were performed in compliance with EU Directive 2010/63/EU, and in agreement with protocols approved by Landesamt für Gesundheit und Soziales (LAGeSo, Berlin), The Rockefeller University (NY), and the National Institutes of Health (NIH) Institutional Animal Care and Use Committees.

Method Details {#sec4.4}
--------------

### Mice {#sec4.4.1}

*Rif1*^*FH/FH*^ ([@bib16]), *Cd19*^*Cre*^ mice ([@bib69]), and *AID(Aicda)*^*−/−*^ ([@bib54]) were previously described. The conditional *Zmynd8*^*F*^ allele bears LoxP sites flanking Exon 4 (ENSMUSE00001273891), and was generated by crossing the knockout first allele with conditional potential *Zmynd8*^*tm1a*^ (European Mouse Mutant Archive, EMMA \#05720) with the *ROSA26*^*Flpo*^ deleter strain (The Jackson Laboratory). Germline transmission was confirmed and positive pups were bred with *Cd19*^*Cre*^ mice to generate *Zmynd8*^*F/F*^*Cd19*^*Cre/+*^ mice. Mice were maintained in a specific pathogen-free (SPF) barrier facility under standardized conditions (20+/−2°C temperature; 55% ± 15% humidity) on a 12 h light/12 h dark cycle. Both male and female mice were used for the experiments. Primers used for genotyping the *Zmynd8*^*F*^ allele are listed in [Table S5](#mmc1){ref-type="supplementary-material"}.

### Cell Cultures and Retroviral Infection {#sec4.4.2}

B lymphocytes were isolated from mouse spleens using anti-CD43 MicroBeads (Miltenyi Biotec) and stimulated to undergo class switching with 25 μg/ml LPS (Sigma-Aldrich) and 5 ng/ml of mouse recombinant IL-4 (Sigma-Aldrich) for CSR to IgG1; 25 μg/ml LPS, 10 ng/ml BAFF (PeproTech) and 2 ng/ml TGFβ (R&D Systems) for CSR to IgG2b; or 25 μg/ml LPS only for CSR to IgG3. Mice 7 to 20 weeks old were used in age-matched groups for splenocytes isolation and CSR assays. CH12 cells ([@bib55]) were stimulated to undergo CSR to IgA by treatment with 5-15 μg/mL αCD40 (BioLegend), 5 ng/ml TGFβ and 5 ng/ml of mouse recombinant IL-4 for 48 h. pMX-ZMYND8-3XFlag retroviral vector was generated by cloning the cDNA for murine ZMYND8 into pMX-IRES-GFP with a C-terminal 3XFlag tag. For CH12 infections with pMX-based retroviral vectors, cells were subjected to 2 rounds of infection with amphotrophic retroviral supernatant, with or without selection with 1 μg/ml of Puromycin (Sigma-Aldrich), followed by activation for 48 h before analysis for CSR efficiency.

### I-DIRT {#sec4.4.3}

B cells from *Rif1*^*FH/FH*^ and *WT* mice were isolated and cultured in SILAC medium composed by RPMI (-Arg, -Lys) medium (Thermo Scientific), L-glutamine, sodium pyruvate, HEPES, 50 μM 2-mercaptoethanol, antibiotic/antimitotic, 10% dialyzed fetal bovine serum (GIBCO), LPS, IL-4 and RP/14 (BD-Biosciences), and supplemented with either ^13^C~6~ L-arginine and ^13^C~6~ L-lysine (Cambridge Isotope Laboratories) (heavy medium; *Rif1*^*FH/FH*^ culture), or non-labeled L-arginine and L-lysine (Sigma-Aldrich) (light medium; *WT* culture). Cells were cultured in SILAC medium for 96 h to ensure near-complete incorporation of the labeled amino acids. For IR treatment, cells were exposed to an X-rays source at a rate of 278.2 Rads/min for 431 s (20 Grays), followed by recovery at 37°C for 45 min.

### Immunoisolation of RIF1^FH^ Complexes {#sec4.4.4}

Rif1-containing complexes were extracted in soluble form and immune-isolated after sub-stoichiometric treatment with glutaraldehyde in order to stabilize labile interactions without perturbing the native composition of protein complexes. Specifically, 2.6x10^9^ cells per culture (*Rif1*^*FH/FH*^ and *WT*) were collected by centrifugation, resuspended in 20 mM HEPES containing 1.2% polyvinylpyrrolidone (Sigma-Aldrich), protease and phosphatase inhibitor cocktails (Roche), 0.5 mM DTT, and frozen in liquid nitrogen. *Rif1*^*FH/FH*^ and *WT* frozen cells were mixed in a 1:1 ratio and cryogenically disrupted by wet milling in a Planetary Ball Mill PM 100 (Retsch). The resulting frozen cell grindate was rapidly thawed in extraction buffer (20mM Tris-Cl pH 8, 150 mM NaCl, 0.5% Igepal CA-630, 1.5 mM MgCl~2~, Benzonase, protease and phosphatase inhibitor) supplemented with 2.5 mM Glutaraldehyde (Sigma-Aldrich), and quenched with 100 mM Tris-CL pH8.0 buffer after 5 min incubation. The lysate was clarified by 10 min centrifugation at 13,000 rpm at 4°C, and immediately incubated with magnetic beads (M-270 epoxy beads, Invitrogen) conjugated with anti-Flag M2 (Sigma-Aldrich) antibody for 1 h at 4°C ([@bib18]). The bead preparation was then washed in extraction buffer, and RIF1^FH^ bait and associated proteins were eluted twice under native conditions by two rounds of incubation with 2.5 μg/μl 3XFlag peptide (Sigma-Aldrich) for 45 min at 4°C with shaking.

### Mass Spectrometric Analysis {#sec4.4.5}

Rif1 baits and co-purifying proteins were resolved by 4%--12% Bis-Tris gel and visualized by Coomassie blue staining. The gel was divided into upper and lower parts along the 39kDa molecular weight marker, with only the lower part fixed. The protein-containing upper and lower parts were cut into 5 and 1 regions respectively, and the gel samples were subjected to in-gel tryptic digestion. Peptides were extracted and purified, analyzed by LCMS using a Thermo Q Exactive Plus mass spectrometer, with a Thermo Easy-nLC 1000 HPLC and a Thermo Easy-Spray electrospray source. Identification and quantification of proteins was performed by searching against a mouse protein sequence database with the MaxQuant software (version 1.2.2.5) ([@bib17]). Protein H/(H+L) ratios were derived using peptides' H/L intensity values in MaxQuant output.

### CRISPR-Cas9 Gene Targeting {#sec4.4.6}

gRNAs for functional screens for loss of CSR function in CH12 were cloned into the U6 cassette of pX458 plasmid (pSpCas9(BB)-2A-GFP, Addgene \#48138). For the loss of CSR screen, 3-6 gRNAs per candidate were cloned and tested, either individually or in pools. CH12 cells were transfected with Cas9-gRNAs expressing constructs via electroporation with Neon Transfection System (Thermo Fisher Scientific), sorted for GFP-positive cells after 40 h, and left to recover for 72 h before activation for CSR analysis. CH12 and MEFs clonal derivatives were generated via electroporation with either single gRNA and WT Cas9-based plasmid (pX458) or gRNA pairs and nickase Cas9-based plasmid. In the latter case, tandem U6 cassettes were cloned into a mutated version of pX458 expressing Cas9^D10A^. Single GFP-positive cells were sorted in 96-well plates and clones were allowed to grow for 12 days (CH12) or 17 days (MEFs) days before expansion. Clones were validated at the level of genomic scar and protein expression. The sequences of the gRNAs employed in these studies are listed in [Table S5](#mmc1){ref-type="supplementary-material"}. The scheme of *Zmynd8* genomic locus in [Figure 1](#fig1){ref-type="fig"}A is adapted from Ensembl ENSMUST00000109269.7. Controls for gRNA-nucleofected CH12 bulk cultures were cells nucleofected either with empty vector or gRNAs against random sequences not present in mouse genome. Controls for CH12 / MEF clonal derivatives included both WT cultures, WT clonal derivatives, and clones derived from targeting CH12 / MEF with random sequences not present in mouse genome.

### Cell Lysates and CoIP Assay {#sec4.4.7}

Co-immunoprecipitation analyses were performed as for I-DIRT pull-down with the only exception that protein elution from magnetic beads was performed by incubation with NuPage LDS Sample buffer (Thermo Fisher) supplemented with 50mM DTT for 10 min at 70C. Where indicated, 10 μM ATMi KU55933 (Tocris Bioscience) was added 1h before irradiation. Western blot analysis of protein levels was performed on whole cell lysates prepared by lysis in RIPA buffer supplemented with Complete EDTA free proteinase inhibitor (Roche). The antibodies used for WB analysis are: anti-Rif1 ([@bib18]), anti-Flag M2 (Sigma-Aldrich), anti-ZMYND8 (Sigma-Aldrich), anti-γH2AX (Millipore), anti-β Actin (Sigma-Aldrich), and anti-53BP1 (Bethyl).

### Flow Cytometry {#sec4.4.8}

For class switching assays, cell suspensions were stained with fluorochrome-conjugated anti-IgG1, anti-IgG3 (BD-Biosciences), anti-IgG2b (BioLegend), or anti-IgA (Southern Biotech). Samples were acquired on a LSRFortessa cell analyzer (BD-Biosciences). Analysis of B cell development and differentiation was performed using anti-CD21/CD35-FITC, anti-IgD-FITC, anti-IgM-PE, anti-IgM-FITC, anti-CD43-PE (BD-Biosciences) and anti-CD23-PE, anti-CD3-PE and anti-CD19-APC (BioLegend) antibodies. For cell proliferation analysis by cell tracking dye dilution, primary B cells were pulsed with 2 μM carboxyfluorescein succinimidyl ester (CFSE) (Invitrogen) or 5 μM CellTrace Violet (Thermofisher) for 10 min at 37C. CFSE/CellTrace covalently labels intracellular molecules, and each cell division halves the signal intensity. For cell cycle analysis, CH12 cells were collected, fixed, and permeabilized using Fixation/Permeabilization Solution (included in BrdU Flow Kit, BD-Biosciences) according to the manufacturer's instructions. BrdU pulse and staining was performed by using BrdU Flow Kit (BD-Biosciences) according to the manufacturer's instructions.

### Mice Immunization and Ig Serum Titers {#sec4.4.9}

For T cell-dependent immunization, 9 to 18 week old mice were injected intraperitoneally with 100 μg alum (Sigma-Aldrich)-precipitated NP-CGG~16~ (Biosearch Technologies). Blood was collected before and at day 7 and 20 after immunization. Serum specific IgM and IgG1 antibodies against NP hapten were determined by ELISA. NP-IgM and NP-IgG1 preparations for standard curves were a kind gift from Klaus Rajewsky (MDC).

### Quantitative PCR {#sec4.4.10}

mRNA levels for AID, pre- and post-spliced germline transcripts, and 3′RR hs eRNA levels were measured as it follows. Total RNA was extracted from splenocytes cultures 48 h after activation using TRIzol (Invitrogen) or RNeasy Mini Kit (QIAGEN) according to manufacturer's instructions, and retro-transcribed with SuperScript VILO cDNA Synthesis Kit (Invitrogen). When using TRIzol, genomic DNA was removed by RapidOut DNA Removal Kit (Thermo Scientific). Transcripts were amplified using StepOnePlus Real-Time PCR System (Applied Biosystems) with Luna Universal qPCR Mastermix (NEB). Primers used for qPCR (this paper; [@bib54], [@bib56], [@bib95]) are listed in [Table S5](#mmc1){ref-type="supplementary-material"}.

### Immunofluorescence {#sec4.4.11}

iMEFs were grown on coverslips overnight. Cells were irradiated (10 Gy IR) and allowed to recover for 90 min or 6 h. Upon fixation with 4% paraformaldehyde (Sigma-Aldrich) and permeabilization with 0.5% Triton X-100, cells were stained with anti-γH2AX (Millipore), rabbit anti-Rif1 serum ([@bib18]), mouse anti-53BP1 (Millipore), mouse anti-Flag M2 (Sigma-Aldrich) or rabbit anti-ZMYND8 (Sigma-Aldrich) antibodies as primary antibodies, and with goat anti-rabbit Alexa546 and goat anti-mouse Alexa488 (Invitrogen) as secondary antibodies. Images were acquired using inverted LSM700 laser scanning confocal microscope (Zeiss).

### Clonogenic Assay {#sec4.4.12}

For the colony formation assay following IR, iMEFs were plated in 60mm dishes, irradiated after 24 hr with the indicated doses and incubated at 37°C in the presence of 5% CO2. After 14 days, colonies were fixed with 15% acetic acid: methanol (v/v) for 5 min and stained with 0.5% Crystal Violet (Sigma-Aldrich) for 30 min for colony visualization. For the colony formation assay in the presence of PARPi (Olaparib/AZD2281, Selleckchem), 0.1, 1, and 5 μM PARPi was added 24 after seeding and cells allowed to grow for 14 days before fixation, with fresh media and PARPi replenished on day 7.

### Metaphase Analysis {#sec4.4.13}

iMEFs were treated with 2 μM PARPi for 21 h followed by 1 h incubation at 37°C with Colcemid (Sigma-Aldrich). Metaphase preparation and aberration analysis were performed as it follows. Cell pellets were resuspended in 0.075M KCl at 37°C for 20 min to perform a hypotonic shock, and washed/fixed with methanol/glacial-acetic acid solution. Metaphase spreads were prepared by dropping fixed cells on microscope slides, which were air-dried and placed at 42°C for 1 h. Giemsa staining was performed by using KaryoMAX Giemsa Stain Solution and Gurr Buffer Tablets (GIBCO). Metaphases were acquired with the Automated Metaphase Finder System Metafer4 (MetaSystems).

### End Resection Assay {#sec4.4.14}

Single guide RNAs targeting two sequences 2276 bp apart within the *ROSA26* locus were cloned into pX458 plasmid (gDSB-1/2). CH12 cells were electroporated with a 1:1 mix of gDSB-1 and gDSB-2 constructs using the Neon Transfection System (Thermo Fisher Scientific), and allowed to recover for 24 h before collection. Genomic DNA was extracted according to standard protocols and individual repair junctions were amplified using nested PCR reactions. PCR products were extracted from agarose gel and sequenced. Single guide RNAs and primers used for the end resection assay are listed in [Table S5](#mmc1){ref-type="supplementary-material"}.

### CRISPR-Cas9-Induced CSR Assay {#sec4.4.15}

Constructs for expression of gRNA-Sμ and gRNA-Sα were generated by cloning single guide RNAs directed to the 5′ Sμ and 3′ Sα regions respectively of the *Igh* locus ([@bib66]) in tandem U6 cassettes on a modified pX458 plasmid backbone. Control construct was generated by cloning random sequences not targeting the mouse genome in tandem U6 cassettes on same plasmid. CH12 cells were electroporated with the constructs using the Neon Transfection System, and allowed to recover for 12 h before CSR analysis.

### MutPE-Seq {#sec4.4.16}

Primary cultures of splenocytes were collected at either 72 h or 96 h post-activation. gDNA was extracted with phenol-chlorofom-isoamyl alcohol, and 5′ Sμ amplicon was amplified and prepared for deep-sequencing by two rounds of PCR. The first round of PCR amplification was performed with Phusion High-Fidelity DNA Polymerase (Thermo Scientific) (annealing temperature of 64.9°C, 15," 20 cycles) and locus-specific primers for 5′ Switch μ. Two/thirds of DNA from the first reaction was used as template for the second reaction (annealing temperature of 64.6°C, 15," 15 cycles) to introduce sequencing adapters and genotype-specific barcodes. Gel-extracted amplicons were pooled and sequenced via 2 × 300bp Paired-end Read Sequencing on an Illumina MiSeq platform. Mutations present in only one of the paired reads were considered a sequencing artifact and discarded. Primers used for MutPE-Seq ([@bib91]) are listed in [Table S5](#mmc1){ref-type="supplementary-material"}.

### ChIP-Seq {#sec4.4.17}

ChIP-seq for ZMYND8 and RNA Pol II were performed as it follows. Splenocytes (72 h post-activation) or CH12 cells (48 h post-activation) were fixed with 1% (16% Formaldehyde Methanol-free, Thermo Scientific) at 37°C for 10 min followed by addition of 1/20 volume of 2.5 M glycine (dissolved in PBS pH 7.4) and swirling. Fixed cells were washed with cold PBS,centrifuged and aliquoted. 20 million cells were resuspended in 100 μL of 1% SDS of RIPA buffer supplemented with Complete EDTA free proteinase inhibitor (Roche) and sonication was performed with a Covaris S220 Focused Ultrasonicator at peak value 105, duty factor 5, cycle/burst 200 for 10 min. After sonication, samples were adjusted to 0.1% SDS final concentration by diluting with non-SDS containing RIPA buffer. Chromatin fragments were then pre-cleaned by incubation with Dynabeads Protein A (Invitrogen) with rotation at 4°C for 1 h, and immunoprecipitated with antibody-bound Dynabeads. 10 ug antibodies specific for ZMYND8 (Sigma-Aldrich) or RNA Pol II polymerase (4H8, Abcam) were used for each sample. DNA libraries were prepared by using Illumina compatible adaptors (Bio Scientific) and sequenced on an Illumina NextSeq 500 Sequencer. FASTQ files were aligned against mouse genome (mm10) using BWA mem ([@bib42]). Processing and peak-calling of ChIP-seq data were accomplished with HOMER ChIP-Seq program ([@bib31]). Peak annotation was done using R and ChIPseeker package ([@bib96]). The schematic representation of the murine *Igh* locus in [Figures 4](#fig4){ref-type="fig"}C, [5](#fig5){ref-type="fig"}A, and [S7](#mmc1){ref-type="supplementary-material"}A encompasses nucleotides 113,175,000-113,441,797 on Chr12.

### RNA-Seq {#sec4.4.18}

Samples used in RNA-seq were cultured in activated and unactivated conditions for 48 h. Cultured cells were collected by centrifugation and RNA was extracted with AllPrep DNA/RNA Mini Kit (QIAGEN). Ribosomal RNA was depleted using Ribo-Zero Gold rRNA Removal Kit (Illumina). Libraries were prepared with TruSeq Stranded Total RNA Library Prep Kit (Illumina). Three biological repeats were performed and run in two lanes on the same flow cells on NextSeq High Output 75 SR (Illumina). For data analysis, reads were pseudo-aligned to an index created from the Ensembl mouse GRCm38.p5 assembly and custom annotations of *Igh* locus features. Transcript-level abundances were quantified using kallisto v0.43.0 ([@bib9]), and subsequently summarized to the gene-level using the R package tximport ([@bib82]). Differential gene expression analysis was performed using DESeq2 ([@bib45]).

### GRO-Seq {#sec4.4.19}

The GRO-Seq analysis was performed on splenocytes 24 h after stimulation with LPS and IL-4 as it follows. Global run-on and library preparation for sequencing was performed on nuclei from 10-15 million cells. After run-on reaction, the RNA was extracted with TRIzol LS Reagent (Invitrogen). RNA was treated with TURBO DNase (Invitrogen), fragmented using RNA Fragmentation Reagents (Invitrogen) and purified by running through BioSpin P-30 Gel Columns (Bio-Rad). The 3′ end of the fragmented RNA was dephosphorylated with T4 Polynucleotide Kinase (NEB) followed by heat-inactivation. Dephosphorylation reactions were purified using anti-BrdU beads (Santa Cruz Biotech) and precipitated overnight. Poly(A)-tailing and cDNA synthesis were performed the next day. For reverse transcription, an oligo allowing custom barcoding during final amplification was used (RT-primer).

After cDNA synthesis, Exonuclease I (NEB) was used to catalyze the removal of excess oligo. The DNA--RNA hybrid was purified using ChIP DNA Clean & Concentrator Kit (Zymo Research Corporation), RNase H (Thermo Scientific) treated and circularized. Circularized cDNAs were relinearized using APE1 (NEB) and were amplified for 12--14 cycles with primers oNTI201 and oNTI200. The final product was ran on a gel, purified, and cleaned up as above. DNA libraries were sequenced on a Hi-Seq 2500 for 50 cycle, single end run and the standard pipeline (1.8.2) was used for image analysis and base calling. Reads were aligned to the National Center for Biotechnology Information mouse genome data (July 2007; NCBI37/mm9) by using the alignment software Bowtie ([@bib38]) with the following options: -S --m 1 --p \[num_of_thread\] -a--best--starta --n 2 --l \[read_length\] --trim5 2. These options report reads that align uniquely to the best stratum and allowing up to 2 mismatches after trimming 2 nucleotides from the 5′ end. For visualization, stranded density tracks were generated by using bedtools genomecov program with a normalizing scale factor to calculate rpm separately for each strand. Rpkm value was calculated for comparative analysis and one sample t.test in R package was used for the p values. Primers used for GRO-Seq ([@bib32]) are listed in [Table S5](#mmc1){ref-type="supplementary-material"}.

### Switch Junction Analysis {#sec4.4.20}

Genomic DNA was extracted from splenocytes stimulated for 96 h with LPS and IL-4, and Sμ-Sγ1 junctions were amplified by two rounds of PCR using Phusion High-Fidelity DNA Polymerase (Thermo Scientific). PCR annealing conditions were 72°C, 2′ and 10 cycles for the first round and 72°C, 2′ and 20 cycles for the second round. PCR products were run on agarose gels, and fragments corresponding to 350-1000 bp were extracted with NucleoSpin DNA Purification Kit (Macherey-Nagel), cloned using TOPO-TA cloning kit (Invitrogen) and sequenced using M13 forward and reverse universal primers. Primers used for Switch junction analysis ([@bib18]) are listed in [Table S5](#mmc1){ref-type="supplementary-material"}.

### SHM Analysis {#sec4.4.21}

Single-cell suspensions from Peyer's patches of 30-31 weeks old mice were first incubated with anti-mouse CD16/32 (BioLegend) and then labeled with B220-FITC-- (BioLegend), CD19-APC-- (BioLegend), CD38-Alexa700-- (Thermo Scientific), and CD95/Fas-PE-- (BD-Biosciences) conjugated antibodies. Non-germinal center (CD38^+^ Fas^−^) and germinal center B cells (CD38^−^ Fas^+^) were sorted on an Aria BD sorter. Genomic DNA was extracted and the 5′ portions of J~H~4 (*Igh*) and J~K~5 (*Igk*) introns were amplified by PCR using Phusion High-Fidelity DNA Polymerase (Thermo Scientific). The 800 bp J~H~4 and 700 bp J~K~5 PCR products were gel extracted, cloned into a pCR2.1 vector using the TOPO TA Cloning Kit (Invitrogen) and sequenced. Mutations were quantified over 510 bp downstream J~H~4 and 536 bp downstream J~K~5 gene segments. Primers used for SHM analysis ([@bib73], [@bib77]) are listed in [Table S5](#mmc1){ref-type="supplementary-material"}.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

The statistical significance of differences between groups/datasets was determined by the Mann--Whitney U test for all data presented in this study, with the following exceptions. The significance for the quantification of RNA Pol II ChIP-seq data ([Figure 5](#fig5){ref-type="fig"}B) was calculated with the Welch 2 sample unpaired t test. The adjusted p values for the quantification of relative transcript levels at hs4, hs1,2, hs3b, hs3a ([Figure 5](#fig5){ref-type="fig"}D) were calculated with the Wald test, and corrected for multiple-testing with the Benjamini-Hochberg method. ^∗∗^ is q \< 1x10ˆ-7 for hs1,2 and q \< 1x10ˆ-9 for hs3b. The pvalues for the differential gene analysis of GRO-Seq data ([Figure S5](#mmc1){ref-type="supplementary-material"}E) were calculated with one-sided one sample t.test (mu = 0) on log2FC. Statistical details of experiments can be found in the figure legends.

Data and Software Availability {#sec4.6}
------------------------------

The accession number for the deep-sequencing data reported in this paper (ChIP-seq, RNA-seq, and GRO-seq) is GEO: [GSE118794](ncbi-geo:GSE118794){#intref0030}. Original imaging and western blot data used to generate any of the figure panels have been deposited at Mendeley: <https://doi.org/10.17632/jktyjvy9hg.1>.
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